{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:10:07Z","timestamp":1766157007501,"version":"build-2065373602"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T00:00:00Z","timestamp":1097539200000},"content-version":"vor","delay-in-days":4302,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1993,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Twenty\u2010one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo\u2010controlled double\u2010blind crossover trial of piracetam (2.4\u2013 16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14\u2010 day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam\/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam\/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double\u2010blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.<\/jats:p>","DOI":"10.1002\/mds.870080112","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T10:06:12Z","timestamp":1104487572000},"page":"63-68","source":"Crossref","is-referenced-by-count":72,"title":["Effectiveness of piracetam in cortical myoclonus"],"prefix":"10.1002","volume":"8","author":[{"given":"P.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. L.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Waegemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. D.","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,12]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_1_2_2","DOI":"10.1093\/brain\/100.3.455"},{"doi-asserted-by":"publisher","key":"e_1_2_1_3_2","DOI":"10.1093\/brain\/112.3.765"},{"key":"e_1_2_1_4_2","first-page":"30","article-title":"Effect therapeutique du piracetam dans un cas de myoclonies d'action post\u2010anoxique","volume":"78","author":"Terwinghe G","year":"1978","journal-title":"Acta Neurol Belg"},{"key":"e_1_2_1_5_2","first-page":"3357","article-title":"Myoclonies d'intention et d'action postanoxiques: amelioration par le piracetam","volume":"41","author":"Cremieux C","year":"1979","journal-title":"Nouv Press Med"},{"key":"e_1_2_1_6_2","first-page":"109","article-title":"Management of a case of myoclonia","volume":"13","author":"Papyrakis JC","year":"1987","journal-title":"Acta Therapeutica"},{"key":"e_1_2_1_7_2","first-page":"197","article-title":"New drugs for posthypoxic action myoclonus: observations from a well studies case","volume":"43","author":"Fahn S.","year":"1986","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_8_2","DOI":"10.1097\/00002826-198602000-00006"},{"doi-asserted-by":"publisher","key":"e_1_2_1_9_2","DOI":"10.1097\/00002826-198812000-00006"},{"doi-asserted-by":"publisher","key":"e_1_2_1_10_2","DOI":"10.1002\/mds.870030306"},{"doi-asserted-by":"publisher","key":"e_1_2_1_11_2","DOI":"10.1111\/j.1365-2125.1979.tb05903.x"},{"doi-asserted-by":"publisher","key":"e_1_2_1_12_2","DOI":"10.1097\/00002826-198904000-00008"},{"key":"e_1_2_1_13_2","first-page":"171","article-title":"Biochemistry and therapeutics of posthypoxic myoclonus","volume":"43","author":"Van Woert MH","year":"1986","journal-title":"Adv Neurol"},{"key":"e_1_2_1_14_2","first-page":"741","article-title":"Measurement of GABA in biological fluids: effect of GABA transaminase inhibitors","volume":"23","author":"Enna SJ","year":"1979","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_15_2","DOI":"10.1111\/j.1600-0404.1982.tb04531.x"},{"key":"e_1_2_1_16_2","first-page":"461","article-title":"Effects de substances stimulantes, sedatives, et hypnotiques sur les taux d'aminoacides cerebrales libres chez le rat","volume":"5","author":"Vial H","year":"1974","journal-title":"J Pharmacol"},{"key":"e_1_2_1_17_2","first-page":"675","article-title":"Piracetam: physiological disposition and mechanism of action","volume":"43","author":"Tacconi MT","year":"1986","journal-title":"Adv Neurol"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870080112","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870080112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:21:41Z","timestamp":1760952101000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870080112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993,1]]}},"alternative-id":["10.1002\/mds.870080112"],"URL":"https:\/\/doi.org\/10.1002\/mds.870080112","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[1993,1]]}}}